Prostate Cancer-Specific of DD3-driven Oncolytic Virus-harboring mK5 Gene

Jiali Hao; Wenjie Xie; Hui Li; Runsheng Li

doi:10.1515/med-2019-0001

Prostate Cancer-Specific of DD3-driven Oncolytic Virus-harboring mK5 Gene

Open Med (Wars). 2018 Dec 24:14:1-9. doi: 10.1515/med-2019-0001. eCollection 2019.

Authors

Jiali Hao¹, Wenjie Xie¹, Hui Li², Runsheng Li³

Affiliations

¹ Xinyuan Institute of Medicine and Biotechnology, Zhejiang SciTech University, Hangzhou 310018, China.
² Shanghai Yuansong biotechnology Co., Ltd., Shanghai, China.
³ Key Laboratory of Contraceptive Drugs and Devices of NPFPC, Shanghai Institute of Planned Parenthood Research, Shanghai, China.

Abstract

Prostate cancer (PCa) is the second most diagnosed cancer in Western male population. In this study, we insert mK5 (the mutational kringle5 of human plasminogen) into a DD3-promoted (differential display code 3) oncolytic adenovirus to construct OncoAd.mK5.DD3. E1A.dE1B, briefly, O^Ad.DD3.mK5. DD3 is one of the most prostate cancer specific promoters which can transcriptionally control adenoviral replication. mK5 has been proved to be able to inhibit the tumor angiogenesis and inhibit cell proliferation. Our results suggested that targeting PCa with O^Ad.DD3.mK5 elicited strong antitumor effect.

Keywords: Angiogenesis; Oncolytic adenovirus; Prostate cancer; mK5.